Click here to view online. Add this email to your safelist.

AstraZeneca logo

COVID-19 vaccine AZD1222 showed robust immune responses in all participants in Phase I/II trial

20 July 2020

Interim results from the ongoing Phase I/II COV001 trial, led by Oxford University, showed AZD1222 was tolerated and generated robust immune responses against the SARS-CoV-2 virus in all evaluated participants.

Read more  Read more

RSS Feed  RSS Feed Twitter  Follow us on Twitter LinkedIn  Follow us on LinkedIn
Legal notice and Terms of Use Privacy policy Cookie policy Site map © AstraZeneca 2020

For more information please visit astrazeneca.com.

If you would like to unsubscribe please click here.